TY - JOUR
T1 - A Traditional Chinese Medicine, Maoto, Suppresses Hepatitis B Virus Production
AU - Rahman, Md Arifur
AU - Ueda, Keiji
AU - Honda, Tomoyuki
N1 - Funding Information:
This study was supported in part by a Grant-in-Aid for the Cooperative Research Project from Institute of Natural Medicine, University of Toyama in 2017 (TH).
Funding Information:
This study was supported in part by AMED under Grant Numbers JP19fk0310101 and JP20fk0310101, JSPS KAKENHI Grant Numbers 18H02664 and 18K19449, and grants from the Takeda Science Foundation, Senri Life Science Foundation, Kobayashi International Scholarship Foundation (TH).
Publisher Copyright:
© Copyright © 2021 Rahman, Ueda and Honda.
PY - 2021/1/22
Y1 - 2021/1/22
N2 - Worldwide, millions of people suffer from hepatitis B virus (HBV) infection, putting them at a high risk of death from liver cirrhosis and cancer. Although effective anti-HBV drugs have been developed, current drugs have some limitations, as most of them have a risk of significant side effects. Therefore, the discovery of safe and effective anti-HBV drugs is still needed. Natural compounds are considered sources of novel, safe and effective therapeutics. In this study, we screened a library of Kampos, traditional herbal medicines, for suppression of HBV production. Among them, we found that maoto reduced extracellular HBV DNA but not extracellular HBsAg during HBV infection, suggesting that it suppressed HBV production by interfering with HBV nucleocapsid incorporation into viral particles. Furthermore, we revealed that maoto reduced the expression of a host gene, Tropomyosin β chain (TPM2), whose downregulation also suppressed HBV production, similarly to maoto. Since the safety of maoto has been already confirmed, maoto can be considered a candidate anti-HBV agent if the effect is confirmed in vivo. In addition, our findings also suggest TPM2 as a novel molecular target for the development of anti-HBV agents.
AB - Worldwide, millions of people suffer from hepatitis B virus (HBV) infection, putting them at a high risk of death from liver cirrhosis and cancer. Although effective anti-HBV drugs have been developed, current drugs have some limitations, as most of them have a risk of significant side effects. Therefore, the discovery of safe and effective anti-HBV drugs is still needed. Natural compounds are considered sources of novel, safe and effective therapeutics. In this study, we screened a library of Kampos, traditional herbal medicines, for suppression of HBV production. Among them, we found that maoto reduced extracellular HBV DNA but not extracellular HBsAg during HBV infection, suggesting that it suppressed HBV production by interfering with HBV nucleocapsid incorporation into viral particles. Furthermore, we revealed that maoto reduced the expression of a host gene, Tropomyosin β chain (TPM2), whose downregulation also suppressed HBV production, similarly to maoto. Since the safety of maoto has been already confirmed, maoto can be considered a candidate anti-HBV agent if the effect is confirmed in vivo. In addition, our findings also suggest TPM2 as a novel molecular target for the development of anti-HBV agents.
KW - cytoskeleton
KW - hepatitis B virus
KW - Kampo
KW - maoto
KW - tropomyosin β chain (TPM2)
UR - http://www.scopus.com/inward/record.url?scp=85100522376&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100522376&partnerID=8YFLogxK
U2 - 10.3389/fcimb.2020.581345
DO - 10.3389/fcimb.2020.581345
M3 - Article
C2 - 33553000
AN - SCOPUS:85100522376
SN - 2235-2988
VL - 10
JO - Frontiers in cellular and infection microbiology
JF - Frontiers in cellular and infection microbiology
M1 - 581345
ER -